Zydus Lifesciences Gets USFDA Approval for Hormone Patch

Mumbai, October 21: Zydus Lifesciences Ltd. has received final approval from the US Food and Drug Administration (USFDA) for its estradiol and levonorgestrel transdermal system, used to treat moderate to severe menopause symptoms. The product is eligible for 180-day Competitive Generic Therapy (CGT) exclusivity.

The approval covers the abbreviated new drug application (ANDA) for the transdermal system containing estradiol and levonorgestrel, equivalent to the reference product Climara Pro.

Product Details and Market Opportunity

The transdermal system is primarily used to treat moderate to severe symptoms of menopause. It may also be used in postmenopausal women to help prevent osteoporosis.

Zydus plans to manufacture the product at its facility in Moraiya, near Ahmedabad, Gujarat. Commercial marketing, where applicable, can begin after the relevant conditions under the US Federal Food, Drug, and Cosmetic Act are met.

According to the company, the reference product had annual sales of approximately US$45.7 million in the United States, based on IQVIA MAT data for August 2026.

As of September 30, 2026, Zydus had received 458 approvals and filed 516 abbreviated new drug applications with the USFDA.

Stock Market Snapshot

The Zydus Lifesciences share price was trading 0.08% lower at ₹1,113 on Wednesday, October 21, 2026, compared with the previous close of ₹1,113.90. The stock opened at ₹1,113.70.

The stock was marginally lower during the session when the company announced the approval. The price movement alone does not establish a direct link to the announcement.

About Zydus Lifesciences

Zydus Lifesciences is an Ahmedabad-based pharmaceutical company with operations spanning formulations, generics, active pharmaceutical ingredients and other healthcare products. It develops and manufactures medicines for domestic and international markets.

Conclusion

The USFDA approval expands Zydus Lifesciences’ product portfolio in the US market. Eligibility for 180-day CGT exclusivity could provide a time-limited competitive opportunity, subject to applicable regulatory conditions and commercial launch requirements.

Source:

• https://www.nseindia.com/get-quote/equity/ZYDUSLIFE/Zydus-Lifesciences-Limited
• https://nsearchives.nseindia.com/corporate/Cadilahc_21102026110803_PressRelease21102026.pdf